Lv6
1970 积分 2022-06-29 加入
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial
28天前
已完结
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
1个月前
已完结
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
1个月前
已完结
Head and neck cancer
2个月前
已完结
Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology
3个月前
已完结
Treatment Profile of CAR-T Cell Therapy Induced Cytokine Release Syndrome and Neurotoxicity: Insights from Real-World Evidence
3个月前
已关闭
An Overview of Cytokine Release Syndrome and Other Side Effects of CAR-T Cell Therapy
3个月前
已关闭
Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy
3个月前
已完结
Anti-cytokine strategies targeting CAR-T cell therapy-induced cytokine release syndrome
3个月前
已关闭
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
